TSitologiya i Genetika 2023, vol. 57, no. 3, 55-56
Cytology and Genetics 2023, vol. 57, no. 3, 272–281, doi: https://www.doi.org/10.3103/S0095452723030106

Cytogenetic analysis of patients with hematological malignancies

Yahya D., Miteva V., Micheva I., Ruseva T., Angelova L.

  1. Department of Medical Genetics, Faculty of Medicine, Medical University of Varna
  2. Department of Internal Diseases, Faculty of Medicine, Medical University of Varna
  3. Laboratory of Medical Genetics, UMHAT «St. Marina», Varna
  4. Clinic of Hematology, UMHAT «St. Marina», Varna

With this study, we aim to summarize and assess the activity and performance of the Cytogenetic sector of the Laboratory of Medical Genetics – Varna, regarding the conventional cytogenetic analysis of bone marrow samples from patients with (onco)hematological diagnoses. Another purpose is to evaluate the tendencies noticed over a period of eleven years to draw conclusions and share our experience. We have performed the analysis with the G-banding technique on 2,653 samples from patients of age 0–93 years by the current European recommendations and the International System for Human Cytogenomic Nomenclature. The greater part of these samples (90.9 %) was with an indication of а hematological malignancy, most commonly Acute myeloid leukemia, Myelodysplastic syndrome, Acute lymphoid leukemia, Chronic myeloid leukemia, and Multiple myeloma. Analysis was successful in 2,215 (83.5 %) – from those normal karyotypes were found in 1492 (67.4 %) and pathology in 723 (32.6 %). Regarding the latter, the most common were complex karyotypes (30.6 %), Philadelphian chromosome (21.3 %), trisomy 8 (5.9 %), and deletion in the long arm of chromosome 5 (4.3 %). Cytogenetic analysis is a method with great impact on the evaluation of many hematological malignancies and for this reason, it remains an essential part of routine assessment of these diseases. The disadvantages of it mainly in the field of oncohematological diseases, recognized by the scientific society and confirmed in our own experience, suggest a need for an additional genetic method to overcome these limitations.

Keywords: cytogenetic analysis, bone marrow, hematologic malignancy, hematologic diseases

TSitologiya i Genetika
2023, vol. 57, no. 3, 55-56

Current Issue
Cytology and Genetics
2023, vol. 57, no. 3, 272–281,
doi: 10.3103/S0095452723030106

Full text and supplemented materials


Avet-Loiseau, H., Attal, M., Moreau, P., et al., Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome, Blood, 2007, vol. 109, no. 8, pp. 3489–3495. https://doi.org/10.1182/blood-2006-08-040410

Ben Haj Ali, A., Amouri, A., Sayeb, M., et al., Cytogenetic and molecular diagnosis of Fanconi anemia revealed two hidden phenotypes: Disorder of sex development and cerebro-oculo-facio-skeletal syndrome, Mol. Gene-t. Genomic Med., 2019, vol.7, no. 7, p. e00694. https://doi.org/10.1002/mgg3.694

Berry, N.K., Scott, R.J., Rowlings, P., et al., Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies, Crit. Rev. Oncol. Hematol., 2019, vol. 142, pp. 58–67. https://doi.org/10.1016/j.critrevonc.2019.07.016

Chalandon, Y., Barnett, M.J., Horsman, D.E., et al., Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission, Biol. Blood Marrow Transplant., 2002, vol. 8, no. 8, pp. 435–443. https://doi.org/10.1053/bbmt.2002.v8.pm12234169

Chen, Y., Cortes, J., Estrov, Z., et al., Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation, J. Clin. Oncol., 2011, vol. 28, no. 18, 2507–2513. https://doi.org/10.1200/JCO.2010.34.2873

Ferguson-Smith, M.A., History and evolution of cytogenetics, Mol. Cytogenet., 2015, vol. 8, p. 19. https://doi.org/10.1186/s13039-015-0125-8

Genescà, E., Morgades, M., González-Gil, C., et al., Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL), Leuk. Res., 2021, vol. 109, p. 106612. https://doi.org/10.1016/j.leukres.2021.106612

Hachmeriyan, M., Levkova, M., Stoyanova, M., et al., Standard karyotyping – a look through the European guidelines, Varna Med. Forum, 2019. https://doi.org/10.14748/vmf.v8i1.5893

Heerema, N.A., Sather, H.N., Sensel, M.G., et al., Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Group, Leuk. Lymphoma, 2000, vol. 36, nos. 5–6, pp. 467–478. https://doi.org/10.3109/10428190009148394

Hemsing, A.L., Hovland, R., Tsykunova, G., et al., Trisomy 8 in acute myeloid leukemia, Expert Rev. Hematol., 2019, vol. 12, no. 11, pp. 947–958. https://doi.org/10.1080/17474086.2019.1657400

Jarošová, M., Holzerová, M., Mihál, V., et al., Complex karyotypes in childhood acute lymphoblastic leukemia: cytogenetic and molecular cytogenetic study of 21 cases, Cancer Genet. Cytogenet., 2003, vol. 145, no. 2, pp. 161–168. https://doi.org/10.1016/s0165-4608(03)00099-2

Kou, Fan, et al., Chromosome abnormalities: new insights into their clinical significance in cancer, Mol. Ther.–Oncolytics, 2020. https://doi.org/10.1016/j.omto.2020.05.010

Lanneaux, J., Poidvin, A., Soole, F., et al., L’anémie de Fanconi en 2012: diagnostic, suivi pédiatrique, traitement, Arch. Pediatr., 2012, vol. 19, no. 10, pp. 1100–1109. https://doi.org/10.1016/j.arcped.2012.07.023

Lübbert, M., Wijermans, P., Kunzmann, R., et al., Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine, Br. J. Haematol., 2001, vol. 114, pp. 349–357. https://doi.org/10.1046/j.1365-2141.2001.02933.x

Marcucci, G., Mrózek, K., Ruppert, A.S., et al., Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461, J. Clin. Oncol., 2004, vol. 22, no. 12, pp. 2410–2418. https://doi.org/10.1200/JCO.2004.03.023

Mikhail, F., Heerema, N., Rao, K., et al., Section E6.1–6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow–acquired chromosomal abnormalities, Genet. Med., 2016. https://doi.org/10.1038/gim.2016.50

Morris, C.M., Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment, Methods Mol. Biol., 2011. https://doi.org/10.1007/978-1-61779-074-4_4

Moreau, P., San Miguel, J., Sonneveld, P., et al., ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 2017, vol. 28, pp. 52–61. https://doi.org/10.1093/annonc/mdx096

Pogosova-Agadjanyan, E.L., Moseley, A., Othus, M., et al., AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report, Biomarker Res., 2020, vol. 8, p. 29. https://doi.org/10.1186/s40364-020-00208-1

Rack, K.A., van den Berg, E., Haferlach, C., et al., European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms, Leukemia, 2019, vol. 33, pp. 1851–1867. https://doi.org/10.1038/s41375-019-0378-z

Richard, D., Hammer, M.D., Donald Doll, M.D., et al., Is it time for a new gold standard? FISH vs cytogenetics in AML diagnosis, Am. J. Clin. Pathol., 2016, vol. 145, no. 3, pp. 430–432. https://doi.org/10.1093/ajcp/aqw008

Sampaio, M.M., Santos, M.L.C., Marques, H.S., et al., Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review, World J. Clin. Oncol., 2021, vol. 12, no. 2, pp. 69–94. https://doi.org/10.5306/wjco.v12.i2.69

Santos, M.F.M., Oliveira, F.C.A.C., Kishimoto, R.K., et al., Pre-analytical parameters associated with unsuccessful karyotyping in myeloid neoplasm: a study of 421 samples, Braz. J. Med. Biol. Res., 2019, vol. 52, no. 2, p. e8194. https://doi.org/10.1590/1414-431X20188194

Sasha, T. and Waclaw, J., Loss of complete cytogenetic response after nilotinib discontinuation, Hematol. Clin. Pract., 2020, vol. 11. https://doi.org/10.5603/Hem.2020.0016

Shahjahani, M., Hadad, E.H., Azizidoost, S., et al., Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility, Oncol. Rev., 2019, vol. 13, p. 389. https://doi.org/10.4081/oncol.2019.389

Stoyanova, M., Tsvetkova, M., Levkova, M., et al., Cytogenetic studies in children—the experience of the laboratory of medical genetics—Varna for a period of 10 years, Pediatria, 2021. ISSN 0479-7876

Tang, G., Hidalgo Lopez, J.E., Wang, S.A., et al., Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera, Haematologica, 2017, vol. 102, no. 9. https://doi.org/10.3324/haematol.2017.165795